ClinicalTrials.gg
RecruitingNCT07187713ACE RenoUpdated Sep 23, 2025

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

A Phase 4 interventional study of ACE Reno in Hypertensive Nephropathy, Auto Immune Disorders and Chronic Kidney Disease, sponsored by Ace Cells Lab Limited. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Ace Cells Lab Limited · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Planned enrollment
4th of 44
300 · median 64
Started
2025
with 16 others
Phase 4
8 of 64
4 open now
Primary completion
2026-08
later than 17 of 27 live
Registered
47th of 64
by date

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 4th largest by planned enrollment of the 44 interventional ones that give a count, is one of 17 that started in 2025, is one of 8 in phase 4, reaches primary completion later than 17 of the 27 other live ones, and was the 47th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria/proteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux/UTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria.

Nephropathy remains a global health burden, with \~9-10% of the population affected by chronic kidney disease (CKD), equating to >750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \~£7 billion annually, projected to rise to \~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension.

ACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS/aldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory/cGMP-mediated (natriuretic peptide-like) pathways.

Read the detailed description

Study Objectives

Primary Objective:

To evaluate the effect of ACE Reno on urinary albumin-to-creatinine ratio (ACR) after 12 weeks of treatment in patients with nephropathy of diverse etiologies.

Secondary Objectives:

To assess the effect of ACE Reno on estimated glomerular filtration rate (eGFR) slope.

To evaluate changes in proteinuria, blood pressure, and patient-reported outcomes.

To assess safety and tolerability.

Exploratory Objectives:

To explore biomarker changes (e.g., TGF-β, cGMP, NGAL, KIM-1). To assess durability of response up to 6 months in responders. Investigational Product (IP) ACE Reno is a sublingual solution (1 mL four times daily for 12 weeks) containing a standardized panel of low-molecular-weight bioactive peptides and amino acids.

Key peptide domains include:

BMP-7-like sequences countering TGF-β-driven fibrosis. HGF-like fragments supporting epithelial repair. Klotho-like motifs antagonizing profibrotic pathways and RAAS/Wnt activity. Natriuretic-peptide-like domains enhancing cGMP signaling, with anti-fibrotic, vasodilatory, and endothelial-protective effects.

No genetic material is present; formulation is peptide-based only. Study Design Type: Prospective, multicenter, interventional, open-label. Model: Single-arm with within-patient comparisons. Duration: 12 weeks treatment + 4 weeks post-treatment safety follow-up. Visits: Screening, Baseline (Day 0), Week 4, Week 8, Week 12, and Week 16 safety call.

Participants

Inclusion:

Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.

Exclusion:

Dialysis at baseline. Recent kidney transplant (\<12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components. Categories (Strata: 17 Subgroups) Diabetic nephropathy - microalbuminuria Diabetic nephropathy - macroalbuminuria Diabetic nephropathy - CKD Stage 3 Diabetic nephropathy - CKD Stage 4-5 (non-dialysis) Hypertensive nephropathy - microalbuminuria Hypertensive nephropathy - proteinuric CKD Hypertensive nephropathy - advanced CKD (3-5) Autoimmune nephropathy - Class II-III Autoimmune nephropathy - Class IV-V Reflux nephropathy - mild/moderate scarring Reflux nephropathy - severe scarring Chronic glomerulonephritis - nephrotic range proteinuria Chronic glomerulonephritis - CKD \<60 mL/min/1.73m² CKD of unknown etiology - Stage 1-2 CKD of unknown etiology - Stage 3-4 ESRD pre-dialysis (eGFR \<15) Post-transplant CKD with proteinuria Sample Size and Rationale

Primary endpoint powering (paired design):

Detect 30% reduction in ACR (δ = ln(0.70) = -0.357), assuming σ = 0.8, r = 0.6 → \~32 analyzable patients needed.

Planned enrollment (pooled cohort, with 17 categories):

\~182 analyzable patients (\~214 enrolled allowing for 15% attrition). Each category will include a minimum of 8-12 patients (more for common etiologies such as diabetic proteinuria).

Total enrollment stratified by prevalence across categories. Endpoints

Primary Endpoint:

Change in urinary ACR from baseline to Week 12 (log-transformed).

Secondary Endpoints:

Change in eGFR slope. Change in 24-h proteinuria (selected patients). Blood pressure change. Patient-reported outcomes (KDQOL-36, EQ-5D). Safety (hyperkalemia, creatinine rise, liver tests, hematology).

Exploratory Endpoints:

Biomarker profiles (TGF-β, cGMP, NGAL, KIM-1). Hospitalization rate. Extended follow-up outcomes at 6 months. Follow-Up Plan

Monthly Visits (Week 4, 8, 12):

Clinical: BP, vitals, weight, adherence. Labs: creatinine/eGFR, electrolytes, liver panel, CBC, urine ACR. Safety: hyperkalemia, creatinine rise. PROs brief (fatigue, QoL).

Final (Week 12):

Primary endpoint assessment (duplicate ACR). PROs full set. Investigator global assessment.

Safety Call (Week 16):

AE/SAE resolution, concomitant therapy updates. Statistical Analysis Primary analysis: Paired t-test and mixed model for repeated measures (MMRM) on log(ACR).

Secondary: eGFR slope via linear mixed model, BP change via ANCOVA, responder rate (≥30% reduction in ACR).

Subgroups: Category-by-time interaction analysis; forest plots for effect estimates.

Multiplicity: Subgroup effects exploratory; overall primary endpoint tested at α=0.05.

03

Conditions studied

  • Hypertensive Nephropathy
  • Auto Immune Disorders
  • Chronic Kidney Disease
  • Chronc Kidney Disease Stage 5
  • Chronic Kidney Disease (Stage 3-4)
  • Chronic Kidney Disease (Stages 4 and 5)
  • Microalbuminuria
  • Diabetic Nephropathies

Keywords

  • chronic kidney disease
  • ckd
  • nephropathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.

Exclusion criteria

Exclusion Criteria:

  • Recent kidney transplant (\<12 months). Uncontrolled acute infection or unstable disease. Pregnancy or lactation. Known to study components.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    1 ml sublingual 4 times daily for 12 weeks

    Participants will receive ACE Reno, a standardized oral transmucosal solution containing low-molecular-weight bioactive peptides and amino acids. The formulation is designed to engage antifibrotic (BMP-7-like, HGF-like, Klotho-like) and vasodilatory/natriuretic peptide-like pathways relevant to glomerular and tubulointerstitial function. No genetic material is present; formulation is peptide-based only.

    Drug: ACE Reno

Interventions

  • DrugACE Reno

    1 ml sublingual 4 times daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in Urinary Albumin-to-Creatinine Ratio (ACR)

    Percent change in log-transformed urinary ACR measured from first-morning urine samples. The primary analysis compares baseline to Week 12 values

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR) slope

    eGFR calculated from serum creatinine using CKD-EPI; slope analyzed via linear mixed model.

    Time frame: Baseline, Week 4, Week 8, Week 12

  2. Change in 24-hour Proteinuria

    Absolute and percent change in 24-hour urinary protein excretion.

    Time frame: Baseline to Week 12 (subset of participants with baseline nephrotic-range proteinuria)

  3. Change in Blood Pressure

    tp adjust BP : systolic \<=140 Diastolic \>100 up to 60 mmHg

    Time frame: Baseline, Week 4, Week 8, Week 12

  4. Safety and Tolerability

    measure 'Full blood count before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

  5. Safety and Tolerability

    measure ALT before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

  6. Safety and Tolerability

    measure 'AST before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

  7. Safety and Tolerability

    measure Bilirubin before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

  8. Safety and Tolerability

    measure 'Urea before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

  9. Safety and Tolerability

    measure 'Creatinine before and after 16 weeks

    Time frame: Throughout treatment and up to Week 16 follow-up

Other outcomes

  1. Hospitalization Events

    Number of hospitalizations related to renal or cardiovascular complications.

    Time frame: Baseline to Week 16

07

Study locations

1 of 1 sites recruiting
  • British Centre For Regenerative medicine BCRMED Global
    Giza, GZ 12311, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.

Of 117 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 23, 2025
StartEst.
Sep 20, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07187713
Lead sponsor
Ace Cells Lab Limited
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Sep 20, 2025 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 23, 2025

Study contacts

Dr. Alaa Abdelkarim M Fouad, MRCPUK SEC
Contact
dralaa@ace-cells.co.uk
+447473922553
Dr. Shireen S Amer, MD
Contact
shireenamer@gmail.com
+20102 3340300
Prof. Dr. Mohammed Yasser Sayyed Saif, PhD
principal investigator · Beni Suef Univeristy
Dr. Alaa Abdelkarim M Fouad, MRCPUK SEC
principal investigator · British Centre for Regenerative medicine BCRMED

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion